HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.

298 Clinical Trials
Leukemia Phase III Active
nct/study# NA / GS-US-546-5857

Phase 3 Study To Evaluate The Safety And Efficacy Of Magrolimab In Combination With Azacitidine Versus Physician’s Choice Of Venetoclax In Combination With Azacitidine Or Intensive Chemotherapy In Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2)

Learn More
Leukemia Phase I/II Active
nct/study# NA / GSK3326595

A Phase I/II Study To Investigate The Safety And Clinical Activity Of GSK3326595 And Other Agents In Subjects With Myelodyplastic Syndrome And Acute Myeloid Leukaemia

Learn More
Leukemia Phase I/II Active
nct/study# NA / KO-MEN-001

KO-539 Menin-KMT2A (MLL) inhibitor Phase ½ R/R AML with NPM1 Mutation) A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemi

Learn More
Leukemia Phase I/II Active
nct/study# NCT02152956 / CP-MGD006-01

A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome

Learn More
Leukemia NA Active
nct/study# NA / MEDISIX-CAR-T

Medisix – Car-T Cell

Learn More
Leukemia NA Active
nct/study# NA / SY-1425-301

Syros SY-1425 Ph III Trial In RARA+ HR-MDS

Learn More

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.